Avoidance of Topical Timolol in Asthmatic Patients Using Albuterol

Mechanism of Interaction

Timolol applied as eye drops is systemically absorbed and, because it blocks both β₁ and β₂ adrenergic receptors, it antagonizes the β₂‑mediated bronchodilator effect of albuterol, potentially precipitating bronchospasm. 2 (Evidence level: pharmacologic/mechanistic study)

The American Heart Association advises that β‑blockers should be avoided in patients with asthma or other obstructive airway diseases because they can cause dangerous bronchoconstriction. 1 (Guideline recommendation)
The National Asthma Education and Prevention Program identifies β‑blockers as a recognized cause of bronchospasm and notes that they may trigger severe bronchospasm when used concurrently with rescue bronchodilators such as albuterol. 1 (Guideline recommendation)

The American Academy of Ophthalmology recommends prostaglandin analogs (e.g., latanoprost, bimatoprost, travoprost, tafluprost) as the preferred first‑line therapy for glaucoma because they have superior intra‑ocular pressure‑lowering efficacy, once‑daily dosing, and lack β‑blocking activity, thereby avoiding interaction with albuterol. 3 (Guideline recommendation)

Systemic absorption of ophthalmic timolol is substantial enough to produce clinically significant β‑blockade, contradicting the assumption that topical administration is free of systemic effects. 4 (Guideline statement)
Even low‑concentration (e.g., 0.25 %) timolol eye drops have been associated with severe bronchospasm in asthmatic patients; therefore, any ophthalmic formulation containing timolol should be avoided in this population. 4 (Guideline warning)